History

·Received CDE indicator case guidance from the Pharmaceutical Inspection Center

·Taiwan Food and Drug Administration (TFDA) has officially approved Ever-Supreme's new drug CAR001 (CAR-T) for Phase I/IIa clinical trials.

·On February 6, 2023, the National Taiwan University Hospital received approval from the Ministry of Health and Welfare for Phase IV autologous immune dendritic cell therapy for solid tumors.

·Awarded the 8th National Industrial Innovation Award by the Ministry of Economic Affairs

·Awarded the 2023 Outstanding Biotechnology Industry Award - Gold Medal

·The U.S. Food and Drug Administration (FDA) has officially approved Ever-Supreme's new drug CAR001 (CAR-T) for Phase I/IIa clinical trials.

·Ever-Supreme was invited to the Presidential Office to meet with the President and jointly celebrate and share the "Outstanding Biotechnology Industry Award".

·Ever-Supreme was invited to a "Presidential Meeting with Recipients of the 2021 Outstanding Biotechnology Industry Award," recognizing Chang Sheng International Biotechnology's achievements in cell therapy.

·In collaboration with China Medical University Hospital, and with approval from the Ministry of Health and Welfare under special regulations, gamma-delta T therapy was developed to treat stage IV solid tumors.

·In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's Special Management Regulations, DC-CIK therapy was used to treat stage I to III lung cancer patients who had failed standard treatments.

·Officially listed on the over-the-counter market

·The first company listed on the over-the-counter market was included in the MSCI index in the shortest possible time.

·Research on CAR001 (CAR-T) allogeneic therapy for solid tumors has been published in the top international journal JITC.
·Awarded the Taiwan Bio Awards Outstanding Biotechnology Industry Award: Potential Benchmark Award

·In collaboration with China Medical University Hospital, CIK therapy for stage IV solid tumors has been approved by the Ministry of Health and Welfare under special regulations.

·Awarded the 18th National Innovation Award for Enterprise Innovation (Precision Immunotherapy Stem Cell Therapy: Dual-Gene Modified Umbilical Cord Mesenchymal Stem Cells for the Treatment of Solid Cancers)

·Awarded a grant from the Ministry of Economic Affairs' A+ Enterprise Innovation and R&D Refinement Program for ADCV01 treatment of GBM.

·CAR001 obtains Japanese patent

·TFDA approves UMSC01 Phase I acute stroke clinical trial case

·FDA approves UMSC01 Phase I acute stroke clinical trial

·In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's Special Management Regulations, DC-CIK therapy was used to treat stage IV solid tumors.

·Assisting TFDA in conducting mock factory inspections

·Awarded the 17th National Innovation Award (Precision Innovation Technology for Dendritic Cell Immunotherapy of Malignant Tumors).
In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's Special Management Regulations, BMSCs were used to treat osteoarthritis.

·In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's Special Management Regulations, BMSCs were used to treat osteoarthritis.

·In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's Special Management Regulations, CIK therapy was developed to treat hematological malignancies.

·Through a factory inspection by the TFDA, TFDA approval was obtained for a Phase 2 clinical trial of the dendritic cell vaccine (ADCV01) for the treatment of malignant brain tumors.
·Received a grant from the Ministry of Economic Affairs' A+ Enterprise Innovation and R&D Refinement Program for UMSC01 treatment of myocardial infarction

·In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's special management regulations, dendritic cell therapy was used to treat stage IV solid cancer.

·In collaboration with China Medical University Hospital, and with the approval of the Ministry of Health and Welfare's Special Management Regulations, dendritic cell therapy was used to treat stage I to III solid cancers that had failed standard treatment.

·UMSC01 was granted a US patent.

·FDA approval has been obtained to conduct a Phase 1 clinical trial of allogeneic stem cell therapy (UMSC01) for the treatment of myocardial infarction.

Obtain exclusive authorization:
·Transplantation of human umbilical cord mesenchymal stem cells into the brains of stroke-stricken rats for functional and structural repair

·After undergoing a factory inspection and obtaining approval from the TFDA, we were able to conduct a Phase I clinical trial of allogeneic stem cells (umsc01) for myocardial infarction.

Obtain exclusive authorization：
·(CAR001) HLA-G chimeric antigen receptor therapy, nucleic acids, receptor expression plasmids, receptor expression applications and pharmaceutical compositions (CAR-T)

Obtain exclusive authorization:
·Dendritic cell tumor vaccine and its preparation method
·Methods for evaluating the suitability of dendritic cell tumor vaccine-based immunotherapy in patients with glioblastoma multiforme and for predicting post-treatment survival.
·Stem cell therapy for brain injury exhibiting IGF1R and the application technology of stem cells

Obtain exclusive authorization:
·Stem cell therapy for myocardial infarction and the application of stem cells with IGF1R expression

·Ever Supreme Bio Technology Established.